Read twice and referred to the Committee on the Judiciary.
Amends 35 U.S.C. §271 to create a statutory safe harbor for infringement claims on method-of-use patents when applicants seek approval and market drugs or biologics using labeling that omits patented uses. Applies to ANDAs (505(j)), 505(b)(2) applications, veterinary counterparts, and biosimilar applications (351(k)), provided labeling, promotion, and marketing do not reference the patented conditions identified to FDA.
Progressives emphasize consumer savings and competition
Relative to its intended legislative type, this bill is a clear, narrowly targeted statutory amendment that establishes a defined safe harbor from method-of-use infringement for specified drug and biologic approval pathways, with concrete textual mechanics and integration into existing statutes.
Amends 35 U.S.C. §271 to create a statutory safe harbor for infringement claims on method-of-use patents when applicants seek approval and market drugs or biologics using labeling that omits patented uses.
Applies to ANDAs (505(j)), 505(b)(2) applications, veterinary counterparts, and biosimilar applications (351(k)), provided labeling, promotion, and marketing do not reference the patented conditions identified to FDA.
Defines promoting, labeling, and biologic-related terms, and makes the rule apply retroactively and prospectively to pending proceedings.
Technically narrow and administrable changes improve clarity for generics but provoke durable opposition from brand patent holders; bipartisan framing helps but passage is uncertain.
Relative to its intended legislative type, this bill is a clear, narrowly targeted statutory amendment that establishes a defined safe harbor from method-of-use infringement for specified drug and biologic approval pathways, with concrete textual mechanics and integration into existing statutes.
Progressives emphasize consumer savings and competition
These are examples from the analysis, not a ranked list of the most-affected groups.
Progressives emphasize consumer savings and competition
Likely broadly supportive: treats the bill as a practical way to enable generics and biosimilars to enter markets for non‑patented uses, lowering prices and expanding access.
Would watch for safeguards against off‑label promotion but views safe harbor as pro‑competition and pro‑consumer.
Cautious but generally favorable: recognizes consumer savings and clearer rules for applicants, balanced against legitimate IP and safety concerns.
Wants detailed FDA implementing guidance and enforcement mechanisms before full endorsement.
Likely opposed: sees the bill as weakening patent rights and investor returns, risking future innovation.
Concerned about patient safety and government interference with IP enforcement.
May accept narrow clarifications but opposes broad safe harbor.
Reached or meaningfully advanced
Reached or meaningfully advanced
Still ahead
Still ahead
Still ahead
Technically narrow and administrable changes improve clarity for generics but provoke durable opposition from brand patent holders; bipartisan framing helps but passage is uncertain.
The bill has not accumulated any surfaced votes yet.
Progressives emphasize consumer savings and competition
Technically narrow and administrable changes improve clarity for generics but provoke durable opposition from brand patent holders; biparti…
Relative to its intended legislative type, this bill is a clear, narrowly targeted statutory amendment that establishes a defined safe harbor from method-of-use infringement for specified drug and biologic approval path…
Go beyond the headline summary with full stakeholder mapping, legislative design analysis, passage barriers, and lens-by-lens tradeoff breakdowns.